DexCom Inc

Most Recent

  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

    By Sarah Collins
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Why Senseonics Holdings Is Up ~5.6% Today

    Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then.

    By Sarah Collins
  • uploads///insulin syringe _
    Company & Industry Overviews

    Analysts’ Views on Tandem Diabetes Care after Its FDA Approval

    After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.

    By Sarah Collins
  • uploads///strategy
    Company & Industry Overviews

    Johnson & Johnson Accepts Sale of Its LifeScan Business

    On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity.

    By Sarah Collins
  • uploads///DIABETES BUSINESS PERFORMANCE
    Earnings Report

    How the Freestyle Libre CGM Opportunity Is Playing Out for ABT

    Abbott Laboratories stated during its second-quarter earnings release that it’s on track for achieving its fiscal 2018 guidance for Libre.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///Part
    Consumer

    The Biggest Detractors for Einhorn’s Greenlight in 2018

    Overall, in 2018, the most significant contributors to Greenlight Capital’s gains included Micron Technology (MU) and Twitter (TWTR).

    By Anuradha Garg
  • uploads///freestyle libre
    Company & Industry Overviews

    Abbott’s Freestyle Libre CGM’s Performance, Growth Prospects

    According to Abbott Laboratories, around two-thirds of diabetes patients have Type-1 diabetes while the rest have Type-2 diabetes.

    By Sarah Collins
  • uploads///GUARDIAN CONNECT
    Company & Industry Overviews

    Guardian Connect Expected to Be Medtronic’s Big Opportunity

    On March 12, Medtronic announced that it has received FDA approval for its stand-alone continuous glucose monitoring system Guardian Connect.

    By Sarah Collins
  • uploads///Intro
    Consumer

    Could Brighthouse Financial Turn Around This Year?

    The most significant contributors to Greenlight Capital’s (GLRE) gains last year included Micron Technology (MU) and Twitter (TWTR).

    By Anuradha Garg
  • uploads///medical device segment
    Company & Industry Overviews

    Abbott’s Freestyle Libre Gets Reimbursement Approval in France

    Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.

    By Sarah Collins
  • uploads///
    Company & Industry Overviews

    A $300 Billion Opportunity Is Waiting for Apple

    In 2017, Apple (AAPL) was selected alongside Samsung (SSNLF), Fitbit (FIT), Alphabet’s (GOOGL) Verily, and others for a US Food and Drug Administration (or FDA) pilot program on digital health software certification.

    By Ruchi Gupta
  • uploads///
    Company & Industry Overviews

    Why Alphabet’s Verily Sought External Funding

    Alphabet’s (GOOGL) Verily subsidiary recently raised $1.0 billion in additional capital from a group of investors led by private equity firm Silver Lake.

    By Neha Gupta
  • uploads///
    Company & Industry Overviews

    Why Apple Might Be Hiring Doctors

    Apple (AAPL) has been quietly recruiting doctors to join its staff, CNBC has reported, citing people familiar with the matter.

    By Ruchi Gupta
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Diabetes Care Stock Soared Over 1,480% in 2018

    Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.

    By Daniel Collins
  • uploads///Dexcom
    Company & Industry Overviews

    A Closer Look at Dexcom Stock’s 117% Year-to-Date Growth

    On November 23, Dexcom (DXCM) stock closed at $124.28, a rise of ~2.20% from its previous day’s close of $121.61.

    By Daniel Collins
  • uploads///equipment _
    Company & Industry Overviews

    Tandem Diabetes Care Stock Has Skyrocketed in 2018

    On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

    By Daniel Collins
  • uploads///TNDM
    Company & Industry Overviews

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.

    By Kenneth Smith
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Should Be on Your Stock Radar

    Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.

    By Kenneth Smith
  • uploads///Diabetes
    Company & Industry Overviews

    A Look into Johnson & Johnson’s Diabetes Care Business

    In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    DexCom Has Reported 150% Growth in 2018 Year-to-Date

    The stock of DexCom (DXCM) has risen 150%, from $57.99 on January 2, 2018, to $143.48 on September 7, 2018.

    By Margaret Patrick
  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care: Stock Still Soaring after Q2 2018 Results

    On August 2, Tandem Diabetes Care (TNDM) stock closed at $31.39. That’s a 9.87% rise from its prior day’s close of $28.57.

    By Daniel Collins
  • uploads///Diabetes
    Company & Industry Overviews

    MDT’s Diabetes Business Could Significantly Boost Its Revenue

    In fiscal Q4 2018, Medtronic’s (MDT) Diabetes segment generated revenue of $645 million compared to $512 million in fiscal 2017.

    By Daniel Collins
  • uploads///TNDM
    Company & Industry Overviews

    What to Expect from Tandem’s Product Pipeline

    T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.

    By Kenneth Smith
  • uploads///diabetes __
    Company & Industry Overviews

    Why Dexcom Stock Rose 6.8% Last Week

    Dexcom (DXCM) rose 6.8% in the week ended March 29, 2018, to close at $74.20.

    By Sarah Collins
  • uploads///GUARDIAN SENSOR
    Company & Industry Overviews

    FDA Approves Arm Indication for Medtronic’s Guardian Sensor 3

    On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3.

    By Sarah Collins
  • uploads///MINIMED MIO
    Company & Industry Overviews

    Medtronic Strengthens Diabetes Business with MiniMed Infusion Set

    On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set.

    By Sarah Collins
  • uploads///ABT STJ product portfolio
    Company & Industry Overviews

    Why Abbott Laboratories’ Product Pipeline Is Expected to Boost 2018

    R&D and product pipeline In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent […]

    By Sarah Collins
  • uploads///GUIDANCE
    Earnings Report

    What’s the Outlook for Medtronic’s Segments in Fiscal 2018?

    During the company’s 2Q18 earnings release on November 21, 2017, Medtronic (MDT) provided guidance for the full fiscal 2018.

    By Sarah Collins
  • uploads///freestyle libre
    Company & Industry Overviews

    Assessing the Role of Freestyle Libre in Abbott’s Diabetes Segment Growth

    Abbott Laboratories (ABT) registered Diabetes sales of ~$373 million in 3Q17, which represented ~14.4% of its total Medical Devices segment sales.

    By Sarah Collins
  • uploads///freestyle libre
    Company & Industry Overviews

    Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval

    On September 27, Abbott Laboratories (ABT) announced the FDA approval of its Flash CGM (continuous glucose monitoring) device, Freestyle Libre.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Abbott Gets UK Reimbursement Approval for Freestyle Libre

    On September 13, 2017, Abbott Laboratories (ABT) announced the reimbursement approval of its Freestyle Libre system.

    By Sarah Collins
  • uploads///ONETOUCH
    Company & Industry Overviews

    Behind Johnson & Johnson’s Recent Medical Device Launches

    JNJ’s new product launches, acquisitions, and collaborations contributed significantly to its Medical Devices segment’s sales.

    By Sarah Collins
  • Company & Industry Overviews

    What Explains the Columbia Select Large Cap Growth Fund’s Poor Showing?

    The short-term performance of the Columbia Select Large Cap Growth Fund – Class A (ELGAX) is excellent, and the past six months have been great for the fund.

    By David Ashworth
  • uploads///ONETOUCH
    Company & Industry Overviews

    Johnson & Johnson’s Latest Medical Device Launches

    Johnson & Johnson has announced the schedule for the launch of the OneTouch Via insulin patch. It plans to launch the device in select US markets by the end of 2016.

    By Sarah Collins
  • uploads///diabetes group
    Company & Industry Overviews

    Medtronic’s Initiative to Advance Type 2 Diabetes Device Business

    Medtronic (MDT) has partnered with Qualcomm to develop a disposable continuous glucose monitor (or CGM) for the type 2 diabetes patient population.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Dexcom Tanks on Profit Booking after Directors Increase Stakes

    Dexcom (DXCM) was the worst-performing stock within the iShares U.S. Medical Devices ETF (IHI) on May 26, 2016.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IHI Remained Flat, Hovering Around Its 52-Week High

    The Markets fell silent and remained flat on April 14, 2016. The iShares US Medical Devices (IHI) closed flat with no gains and no losses for the day.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    The iShares US Medical Devices ETF (IHI) Has Put Nothing under the Tree in December—Yet

    The iShares US Medical Devices ETF (IHI) rose by 1.15% on December 15, closing at $122.32, 2% higher than its 100-day moving average price of $119.8.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.